Journal of Digestive Cancer Research

Korean Society of Gastrointestinal Cancer Research (대한소화기암연구학회)
권호 표지
DOI QR코드

DOI QR Code

Mechanism and Treatment of Chemotherapy-induced Peripheral Neuropathy

항암치료와 연관된 신경병증의 발생 기전 및 치료

  • Dong Kee Jang (Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center)
  • 장동기 (서울대학교 의과대학 내과학교실, 서울특별시 보라매병원)
  • Received : 2022.11.09
  • Accepted : 2022.12.26
  • Published : 2023.04.20
Download PDF
⟨ Previous Next ⟩

Abstract

One of the most common side effects of chemotherapeutic agents is chemotherapy-induced peripheral neuropathy (CIPN). The occurrence of CIPN is increasing as the survival rate of patients with cancer improves and the cumulative dose or duration of neurotoxic drugs increases. Approximately 30-40% of patients receiving neurologically toxic drugs experience CIPN, which eventually increases the burden of medical expenses. However, preventive measures against CIPN have not yet been established. Clinical trials have tested various drugs for the management of neuropathic pain, but only duloxetine has shown any significant effect. Further studies should evaluate nonpharmaceutical treatments, such as exercise.

Keywords

References

  1. Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB. Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012;2012:913848. https://doi.org/10.1155/2012/913848 
  2. Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 2017;81:772-781. https://doi.org/10.1002/ana.24951 
  3. Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2014;32:1941-1967. https://doi.org/10.1200/JCO.2013.54.0914 
  4. Krarup-Hansen A, Helweg-Larsen S, Schmalbruch H, Rorth M, Krarup C. Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies. Brain 2007;130:1076-1088. https://doi.org/10.1093/brain/awl356 
  5. Tzatha E, DeAngelis LM. Chemotherapy-induced peripheral neuropathy. Oncology (Williston Park) 2016;30:240-244. 
  6. McDonald ES, Windebank AJ. Cisplatin-induced apoptosis of DRG neurons involves bax redistribution and cytochrome c release but not fas receptor signaling. Neurobiol Dis 2002;9:220-233. https://doi.org/10.1006/nbdi.2001.0468 
  7. Podratz JL, Knight AM, Ta LE, et al. Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis 2011;41:661-668. https://doi.org/10.1016/j.nbd.2010.11.017 
  8. Sittl R, Lampert A, Huth T, et al. Anticancer drug oxaliplatin induces acute cooling-aggravated neuropathy via sodium channel subtype Na(V)1.6-resurgent and persistent current. Proc Natl Acad Sci U S A 2012;109:6704-6709. https://doi.org/10.1073/pnas.1118058109 
  9. Conde C, Caceres A. Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 2009;10:319-332. https://doi.org/10.1038/nrn2631 
  10. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 2016;60:210-225. https://doi.org/10.1016/j.ejca.2016.02.024 
  11. Johnson C, Pankratz VS, Velazquez AI, et al. Candidate pathway-based genetic association study of platinum and platinum-taxane related toxicity in a cohort of primary lung cancer patients. J Neurol Sci 2015;349:124-128. https://doi.org/10.1016/j.jns.2014.12.041 
  12. Abraham JE, Guo Q, Dorling L, et al. Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with paclitaxel. Clin Cancer Res 2014;20:2466-2475. https://doi.org/10.1158/1078-0432.CCR-13-3232 
  13. Apellaniz-Ruiz M, Lee MY, Sanchez-Barroso L, et al. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy. Clin Cancer Res 2015;21:322-328. https://doi.org/10.1158/1078-0432.CCR-14-1758 
  14. Baldwin RM, Owzar K, Zembutsu H, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012;18:5099-5109. https://doi.org/10.1158/1078-0432.CCR-12-1590 
  15. Boora GK, Kulkarni AA, Kanwar R, et al. Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). J Neurol Sci 2015;357:35-40. https://doi.org/10.1016/j.jns.2015.06.056 
  16. Chen J, Yin J, Li X, et al. WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients. Int J Mol Sci 2014;15:21011-21027. https://doi.org/10.3390/ijms151121011 
  17. Custodio A, Moreno-Rubio J, Aparicio J, et al. Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study. Ann Oncol 2014;25:398-403. https://doi.org/10.1093/annonc/mdt546 
  18. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA. Glutathione S-transferase P1 polymorphism (Il-e105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006;12:3050-3056. https://doi.org/10.1158/1078-0432.CCR-05-2076 
  19. Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL. National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support Care Cancer 2016;24:1439-1447. https://doi.org/10.1007/s00520-015-3063-4 
  20. Smith EM, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309:1359-1367. https://doi.org/10.1001/jama.2013.2813 
  21. Kleckner IR, Kamen C, Gewandter JS, et al. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 2018;26:1019-1028. https://doi.org/10.1007/s00520-017-4013-0